Comparative Pharmacology
Head-to-head clinical analysis: AMBRISENTAN versus ASCLERA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMBRISENTAN versus ASCLERA.
AMBRISENTAN vs ASCLERA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Endothelin receptor antagonist (ERA) that selectively binds to endothelin type A (ETA) receptors in pulmonary vascular smooth muscle, blocking endothelin-1-mediated vasoconstriction and proliferation.
ASCLERA (corticotropin) is a proopiomelanocortin (POMC) analog that stimulates the adrenal cortex to release cortisol, corticosterone, and aldosterone, increasing corticosteroid levels. It also has immunomodulatory and anti-inflammatory effects mediated through melanocortin receptors.
10 mg orally once daily, with or without food, for patients not receiving cyclosporine. For patients receiving cyclosporine, reduce dose to 5 mg once daily.
Adults: 240 mg/m2 intravenously over 2 hours on day 1 of each 21-day cycle.
None Documented
None Documented
Clinical Note
moderateAmbrisentan + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Ambrisentan."
Clinical Note
moderateAmbrisentan + Methylphenidate
"Ambrisentan may decrease the antihypertensive activities of Methylphenidate."
Clinical Note
moderateAmbrisentan + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Ambrisentan."
Clinical Note
moderateAmbrisentan + Erythromycin
Terminal elimination half-life is approximately 9 hours (range 4–20 hours) in healthy subjects; no significant accumulation is observed with once-daily dosing.
Terminal elimination half-life is 12-15 hours. In patients with moderate-to-severe renal impairment (CrCl < 30 mL/min), half-life may increase to 30-40 hours, requiring dose adjustment.
Primarily via nonrenal pathways, with fecal excretion accounting for approximately 77% of a radiolabeled dose (as unchanged drug and metabolites) and renal excretion for about 22% (mostly as metabolites).
Renal excretion of unchanged drug accounts for 60-70% of administered dose; fecal/biliary elimination contributes 20-30%.
Category C
Category C
Endothelin Receptor Antagonist
Endothelin Receptor Antagonist
"The metabolism of Erythromycin can be decreased when combined with Ambrisentan."